main content start

MedEnrich | Página principal

Continue Watching

últimos vidéos

últimos vidéos

Brightcove Home Latest Listing

Cáncer de mama

Cáncer de mama

Brightcove Cards Listing

Cáncer de próstata

Brightcove Cards Listing

Mieloma múltiple

Mieloma múltiple

Brightcove Cards Listing

Popular en MedEnrich

Popular in Sin nombre
  • Myelodysplastic Syndromes8m 45s

    Current Challenges in MDS Diagnosis and Consequences

    Bone marrow examination-based diagnosis of MDS with either biopsy or aspirate remains standard of care but is associated with pain, bleeding, difficulty to use the same in elderly patients and hIgh interobserver variability.
    non invasive mds diagnosis web based mds diagnosis tools
  • Cancer de prostata7m 0s

    Abiraterone in Metastatic Castration Sensitive Prostate Cancer

    Two Clinical Trials with long term follow up (LATITIDUE 52 Months) & STAMEPDE (72 Months) have confirmed effectiveness of Abiraterone in mHSPC.
    stampede clinical trial latitude clinical trial abiraterone mhspc
  • Mieloma múltiple4m 12s

    Key Practice Points -Myeloma Related Renal Impairment

    In patients with renal impairment primary goal is improvement of Renal Function which is associated with improved treatment outcomes. 50% of patients present renal impairment and renal impairment is severe in 15% of patients.
    myeloma renal impairment key practice points
  • Myelodysplastic Syndromes31m 24s

    Improving Diagnosis of MDS -Innovative Solutions

    Modern Web -Based digital tools based on 10 routinely used clinical parameters and Gradient Based Model can help in non-invasive diagnosis of MDS.
    mds diagnosis web based diagnosis her2negative mbc
  • Oncology4m 9s

    Cardio Oncology in Prostate Cancer

    Major cardiovascular toxicities associated with the prostate cancer treatment include arrhythmias, atherosclerosis, myocardial Infarction, hypertension & cardiomyopathy. Toxicities vary with the type of agent used in Prostate Cancer Treatment.
    abcde protocol cardio oncology prostate cancer
  • Cáncer de mama8m 55s

    Understanding HER-2 Low Breast Cancer Entity & Treatment Strategy

    Tumors with a HER-2 immunohistochemistry (IHC) score of 1 + or 2 + and a negative molecular reflex test have been classified as HER2-low Breast Cancers.
    trastuzumab-deruxtecan (t-dxd) her2 low breast cancers
  • Cáncer de mama3m 36s

    Tumor Infiltrating Lymphocytes as Predictive Biomarker in Breast Cancer

    Immune cells known as tumor-infiltrating lymphocytes (TILs) are thought to be a promising, affordable biomarker with prognostic and predictive potential.
    tumor-infiltrating lymphocytes (tils) promising biomarker
  • Cáncer de mama11m 28s

    ESR1 Mutation in Hormone Receptor Positive Advanced Breast Cancer

    ESR1 mutation leads to ligand independent activation of estrogen receptor. ESR1 mutations were first described in 1997 & their role remain underestimated as initial research was focused on primary tumor wherein these mutations were absent.
    aromatase inhibitor resistance hr +ve mbc esr1 mutation fulvestrant
  • Mieloma múltiple7m 47s

    Exploring Optimal Duration of Lenalidomide Maintenance after ASCT

    Best evidence for Lenalidomide maintenance after ASCT came from Meta-analysis of 3 trials (McCarthy et al, JCO 207) confirmed significant OS benefit with Lenalidomide maintenance.
    lenalidomide maintenance myeloma xi duration of maintenance
  • Myelodysplastic Syndromes17m 59s

    Genomics of AML -Therapeutic and Prognostic Implications

    ~40% of AML patients have targetable mutations. Younger patients often have FLT3-ITD or FLT3- TKD mutation. Mutations IDH-1 , IDH-2 & t-53 mutations are more common in elderly patients.
    idh 1& 2 mutations flt3-tkd mutations bcl2 inhibtors genomics of aml
  • Seminarios web anteriores

    Seminarios web anteriores

    Webinar Cards Listing



    Medbytes Cards Listing
    Hi, can I help?
    Chat de ayudaX
    Equipo de soporte
    ¡Hola! ¿Cómo puedo ayudarlo/a hoy?
    Por favor seleccione alguna de las siguientes opciones.

    Buscar información

    Problemas con el inicio de sesión o registro

    Compartir un comentario